OMER Omeros Corporation

18.40
-0.12  -1%
Previous Close 18.52
Open 18.50
Price To book 96.84
Market Cap 883269368
Shares 48,003,770
Volume 166,063
Short Ratio 9.74
Av. Daily Volume 958,940

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171190891
  2. 8-K - Current report 171190782
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 171183636
  4. 8-K - Current report 171139924
  5. 8-K - Current report 171124735

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 4Q 2017.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial planned.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 2 initiated Feb 2014. Trial was placed on hold due to preclinical concerns. To resume with with dosing limitations
OMER824
Huntington disease
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)

Latest News

  1. New Research Coverage Highlights Wells Fargo, Omeros, Uranium Energy, Advisory Board, Twenty-First Century Fox, and SiteOne Landscape Supply — Consolidated Revenues, Company Growth, and Expectations for 2018
  2. Omeros Corp. – Value Analysis (NASDAQ:OMER) : November 17, 2017
  3. Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 16, 2017
  4. Edited Transcript of OMER earnings conference call or presentation 9-Nov-17 9:30pm GMT
  5. 5 Small Biotechs Receive Shots in the Arm
  6. This Biotech Just Rose By A Third On Its Earnings — But Is It In Trouble?
  7. Omeros Story Continues to Get Better, but Reimbursement Risk Remains
  8. This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today
  9. Can Omeros Top-Line Growth Continue?
  10. Omeros shares surge 17% after Q3 revenue beat
  11. Today’s Research Reports on Trending Tickers: Opko Health and Omeros Corporation
  12. Omeros Corporation (OMER) Shares Soar Following Strong Quarter
  13. Omeros reports 3Q loss
  14. Omeros Corporation Reports Third Quarter 2017 Financial Results
  15. Omeros Corporation (OMER): Extended Follow-Up Data Evaluating OMS721 Shows Improvement in Patients with IgA
  16. Extended Improvement in OMS721-Treated Patients with IgA Nephropathy Presented at American Society of Nephrology Annual Meeting
  17. Omeros Corporation to Announce Third Quarter 2017 Financial Results on November 9, 2017
  18. ETFs with exposure to Omeros Corp. : November 3, 2017
  19. Today's Research Reports on Trending Tickers: Omeros Corporation and Myriad Genetics
  20. Omeros Announces Upcoming Presentation of Clinical OMS721 Data at the American Society of Nephrology Annual Meeting

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171190891
  2. 8-K - Current report 171190782
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 171183636
  4. 8-K - Current report 171139924
  5. 8-K - Current report 171124735
  6. 8-K - Current report 171046810
  7. 8-K - Current report 171039349
  8. 424B5 - Prospectus [Rule 424(b)(5)] 171037134
  9. 424B5 - Prospectus [Rule 424(b)(5)] 171030956
  10. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 171030029